U.S. markets closed
  • S&P 500

    4,166.45
    -55.41 (-1.31%)
     
  • Dow 30

    33,290.08
    -533.37 (-1.58%)
     
  • Nasdaq

    14,030.38
    -130.97 (-0.92%)
     
  • Russell 2000

    2,237.75
    -49.71 (-2.17%)
     
  • Crude Oil

    71.50
    +0.46 (+0.65%)
     
  • Gold

    1,763.90
    -10.90 (-0.61%)
     
  • Silver

    25.84
    -0.01 (-0.04%)
     
  • EUR/USD

    1.1865
    -0.0045 (-0.38%)
     
  • 10-Yr Bond

    1.4500
    -0.0610 (-4.04%)
     
  • GBP/USD

    1.3809
    -0.0115 (-0.83%)
     
  • USD/JPY

    110.1500
    -0.0810 (-0.07%)
     
  • BTC-USD

    33,959.70
    -1,970.43 (-5.48%)
     
  • CMC Crypto 200

    888.52
    -51.42 (-5.47%)
     
  • FTSE 100

    7,017.47
    -135.96 (-1.90%)
     
  • Nikkei 225

    28,964.08
    -54.25 (-0.19%)
     

Eli Lilly ends supply agreement with U.S. govt for COVID-19 antibody drug

  • Oops!
    Something went wrong.
    Please try again later.

April 12 (Reuters) - Eli Lilly and Co said on Monday it had terminated a supply agreement with the U.S. government for its COVID-19 antibody drug and would now focus on selling it in combination with another therapy.

Lilly and the U.S. government have agreed to modify the purchase agreement for the drug, bamlanivimab, and focus on its supply with etesevimab, the company said. (Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)